Freenome (NASDAQ:FRNM – Get Free Report) has been given an average recommendation of “Moderate Buy” by the six research firms that are currently covering the stock, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating and five have assigned a buy rating to the company. The average 1-year target price among brokers that have covered the stock in the last year is $18.00.
Several research analysts have recently commented on FRNM shares. Leerink Partners began coverage on Freenome in a research note on Friday, August 14th. They issued an “outperform” rating and a $18.00 price objective on the stock. TD Cowen initiated coverage on Freenome in a research report on Tuesday, August 18th. They set a “buy” rating and a $17.00 price objective on the stock. Weiss Ratings initiated coverage on Freenome in a research note on Monday, August 24th. They set a “sell (d+)” rating for the company. BTIG Research initiated coverage on shares of Freenome in a report on Monday, August 17th. They issued a “buy” rating and a $17.00 target price for the company. Finally, Guggenheim started coverage on shares of Freenome in a report on Thursday, August 20th. They issued a “buy” rating and a $21.00 target price for the company.
View Our Latest Report on Freenome
Freenome Stock Down 2.8%
NASDAQ:FRNM opened at $10.18 on Friday. The firm’s 50-day moving average is $14.44. Freenome has a 52-week low of $9.71 and a 52-week high of $17.50. The company has a market capitalization of $1.09 billion, a price-to-earnings ratio of -169.64 and a beta of 0.60.
About Freenome
Freenome is a biotechnology company developing blood-based tests designed to detect cancer at an early stage. Its platform combines artificial intelligence with multiomics, including genomic, epigenomic and proteomic signals found in blood, to identify patterns associated with cancer.
The company has focused its research and clinical development efforts on screening for colorectal cancer and other common cancers. Freenome’s products are intended to support noninvasive screening and may complement or provide an alternative to certain conventional screening methods, subject to regulatory review and approval.
Founded in 2014, Freenome is headquartered in South San Francisco, California.
Featured Stories
- Five stocks we like better than Freenome
- Dutch Bros Gave Wall Street What It Wanted, So Why Did the Stock Crater?
- Astera Labs Just Crushed Earnings—So Why Are Analysts Cutting Price Targets?
- Sandisk Shares Are Oversold: Bargain or Value Trap?
- IonQ’s Record Revenue Includes a Big SkyWater Boost: Does That Change the Story?
Receive News & Ratings for Freenome Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Freenome and related companies with MarketBeat.com's FREE daily email newsletter.
